Although few RKIP-targeted therapies currently exist, the clinical trial by Wang et al. [209] showcased the viability of RKIP-targeted therapies as the transfected plasmid that triggered overexpression of RKIP resulted in the inhibition of invasion and cancer metastasis of NSCLC cells. Here, PEBP1 is linked to cancer.